Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03588975 · ClinicalTrials.gov registry record · Phase 3

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

A Phase 3 study of Chondral Defect and Articular Cartilage Defect, sponsored by Vericel Corporation.

Recruiting
Registry status
Phase 3
Development phase
45
Enrollment target
12
Study locations

NCT03588975: Recruiting Phase 3 study of Chondral Defect and Articular Cartilage Defect, sponsored by Vericel Corporation.

NCT03588975 is a Phase 3 study of Chondral Defect and Articular Cartilage Defect that is actively recruiting participants, run by Vericel Corporation. The registered enrollment target is 45 participants, below the 290-participant average among 3 other Chondral Defect trials with a reported enrollment target (84% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03588975, a Phase 3 study of Chondral Defect and Articular Cartilage Defect, is actively recruiting participants, sponsored by Vericel Corporation.

RECRUITING
Registry status
Phase 3
Development phase
45 participants
Enrollment target
12
Study locations

Study Summary

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Primary Outcome

A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities

Interventions

  • BIOLOGICAL MACI
  • PROCEDURE microfracture

Study Locations (12)

California

  • Stanford University - Palo Alto
  • Shriner's Hospital for Children Northern California - Sacramento
  • University of California Davis Health - Sacramento

Ohio

  • Akron Children's Hospital - Akron
  • The Ohio State University Jameson Crane Sports Medicine Institute - Columbus

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Penn Sports Medicine Center - Philadelphia

Louisiana

  • Ochsner Sports Medicine Institute - New Orleans

Maryland

  • Johns Hopkins Outpatient Center - Baltimore

Michigan

  • University of Michigan - Ann Arbor

Texas

  • Texas Children's Hospital - Houston

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2018-10-24
Est. Completion 2027-06
Phase Phase 3
Vericel Corporation

11 total trials

What NCT03588975 shows while recruiting

NCT03588975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 290-participant average among 3 other Chondral Defect trials with a reported enrollment target (84% lower).

The record links to 4 conditions, with Chondral Defect appearing as the primary indexed condition, and to 2 interventions - of which MACI is the first listed.

NCT03588975 lists 12 locations in 8 states (California, Ohio, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT03588975 about?

NCT03588975 is a clinical study titled "A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee". The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

What is the current status of trial NCT03588975?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2018-10-24. Estimated completion is 2027-06.

What conditions does trial NCT03588975 study?

This clinical trial studies the following conditions: Chondral Defect, Articular Cartilage Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Disorder of Knee.

What interventions are being tested in trial NCT03588975?

The interventions under investigation include: MACI (BIOLOGICAL), microfracture (PROCEDURE).

Who is sponsoring clinical trial NCT03588975?

This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03588975 being conducted?

This trial has 12 study locations across California, Louisiana, Maryland, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chondral Defect

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03588975, the US trial registry maintained by the National Library of Medicine. NCT03588975 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.